NovoCure Reports Cybersecurity Incident Affecting Patient and Employee Data In mid-August 2026, NovoCure Limited, a medical device and oncology therapy company headquartered in Jersey, detected unauthorized access to a portion of its information systems. The company, which trades on the Nasdaq (NVCR), promptly activated its cybersecurity response plan, containing the breach and launching an internal investigation with support from independent forensic experts. The exposed data included: - Internal patient ID numbers for over 1,400 U.S. patient records (no names or direct identifiers were compromised). - Additional identifying information for fewer than 50 patients in the western U.S. - General contact details for healthcare providers and NovoCure employees, such as job titles and phone numbers. NovoCure confirmed that no medical treatment devices were accessed, and its operational systems remain fully functional. The company is assessing regulatory and legal notification requirements, including potential disclosures to affected patients. While the incident is not currently expected to have a material financial impact, NovoCure stated it would file an amended report if further investigation reveals significant risks. The company continues to evaluate the scope and implications of the breach.